Paratek expands commercial portfolio with Optinose
Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings.
The companies signed a definitive merger agreement in March 2025.
The portfolio of Paratek now includes its lead antibiotic, Nuzyra (omadacycline), and Optinose's Xhance (fluticasone propionate).
The acquisition encompasses all outstanding shares of Optinose, including debt assumption and full payment of contingent value rights (CVRs).
Optinose shareholders approved the merger on 16 May. The transaction was supported by capital from Paratek, Novo Holdings and B-FLEXION Life Sciences, and debt financing from Oaktree Capital Management funds.
The shareholders received $9 per share in cash and CVRs for up to $5 per share, contingent upon Xhance reaching certain net revenue milestones.
Paratek has agreed to pay $1 per share on Xhance's achievement of $150m in net sales in any calendar year before 31 December 2028, and an additional $4 per share if they reach $225m before 31 December 2029.
Nuzyra is designed to combat tetracycline resistance and functions against a broad range of bacteria, including drug-resistant strains.
It is available in both oral and intravenous formulations for treating community-acquired bacterial pneumonia and acute bacterial skin infections.
Xhance, a drug-device combination product, utilises the exhalation delivery system, which delivers the topical steroid to the deep nasal cavity areas.
Paratek Pharmaceuticals CEO Evan Loh stated: "Adding Xhance to our portfolio is a pivotal first step in achieving our long-term vision to become a multi-product speciality therapeutics company, focused on addressing significant unmet medical needs.
"This transaction establishes a strong platform for us to continue to leverage these capabilities as we move forward to explore opportunities to expand our portfolio through future product acquisitions."
Lazard and Skadden, Arps, Slate and Meagher & Flom provided exclusive financial and legal advisory services to Paratek.
Evercore and Hogan Lovells US provided exclusive financial and legal advisory services to Optinose.
"Paratek expands commercial portfolio with Optinose" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22-05-2025
- Yahoo
Paratek expands commercial portfolio with Optinose
Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings. The companies signed a definitive merger agreement in March 2025. The portfolio of Paratek now includes its lead antibiotic, Nuzyra (omadacycline), and Optinose's Xhance (fluticasone propionate). The acquisition encompasses all outstanding shares of Optinose, including debt assumption and full payment of contingent value rights (CVRs). Optinose shareholders approved the merger on 16 May. The transaction was supported by capital from Paratek, Novo Holdings and B-FLEXION Life Sciences, and debt financing from Oaktree Capital Management funds. The shareholders received $9 per share in cash and CVRs for up to $5 per share, contingent upon Xhance reaching certain net revenue milestones. Paratek has agreed to pay $1 per share on Xhance's achievement of $150m in net sales in any calendar year before 31 December 2028, and an additional $4 per share if they reach $225m before 31 December 2029. Nuzyra is designed to combat tetracycline resistance and functions against a broad range of bacteria, including drug-resistant strains. It is available in both oral and intravenous formulations for treating community-acquired bacterial pneumonia and acute bacterial skin infections. Xhance, a drug-device combination product, utilises the exhalation delivery system, which delivers the topical steroid to the deep nasal cavity areas. Paratek Pharmaceuticals CEO Evan Loh stated: "Adding Xhance to our portfolio is a pivotal first step in achieving our long-term vision to become a multi-product speciality therapeutics company, focused on addressing significant unmet medical needs. "This transaction establishes a strong platform for us to continue to leverage these capabilities as we move forward to explore opportunities to expand our portfolio through future product acquisitions." Lazard and Skadden, Arps, Slate and Meagher & Flom provided exclusive financial and legal advisory services to Paratek. Evercore and Hogan Lovells US provided exclusive financial and legal advisory services to Optinose. "Paratek expands commercial portfolio with Optinose" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
15-05-2025
- Yahoo
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
OptiNose (OPTN) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.80 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -36.49%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.70 per share when it actually produced a loss of $0.03, delivering a surprise of 95.71%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. OptiNose , which belongs to the Zacks Medical - Drugs industry, posted revenues of $18.51 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.58%. This compares to year-ago revenues of $14.88 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. OptiNose shares have added about 41.5% since the beginning of the year versus the S&P 500's gain of 0.1%. While OptiNose has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for OptiNose: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.40 on $24.2 million in revenues for the coming quarter and -$3.13 on $91.03 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, MediWound (MDWD), is yet to report results for the quarter ended March 2025. The results are expected to be released on May 21. This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.65 per share in its upcoming report, which represents a year-over-year change of -66.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. MediWound's revenues are expected to be $5.1 million, up 2.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OptiNose, Inc. (OPTN) : Free Stock Analysis Report MediWound Ltd. (MDWD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
22-03-2025
- Yahoo
Why OptiNose Inc. (OPTN) Surged On Thursday?
We recently published a list of . In this article, we are going to take a look at where OptiNose Inc. (NASDAQ:OPTN) stands against other micro-, small-cap firms that dominate Thursday's gains. The stock market edged lower on Thursday, erasing gains from the previous trading day that was buoyed by the Federal Reserve's decision to keep rates unchanged. The tech-heavy Nasdaq decreased by 0.33 percent, the S&P 500 declined by 0.22 percent, and the Dow Jones dipped by 0.03 percent. On Thursday, investors immediately booked profits following the lack of fresh catalysts to further boost buying appetite. However, 10 companies under the micro- to small-cap sectors noticeably defied market pessimism, having surged by double to triple digits. In this article, we have identified Thursday's 10 best performers and detailed the reasons behind their gains. We classify micro-cap companies as those between $50 million and $300 million in market capitalization, while small-cap firms are those with $300 million and $2 billion in market capitalization. A white-coat wearing pharmacist holding a bottle of a specialized therapeutic product. OptiNose grew its share prices by 52.50 percent on Thursday to finish at $9.15 apiece as investors took heart from news that it is set to be acquired by Paratek Pharmaceuticals for $330 million. In a statement on Thursday, Paratek announced that it entered into a definitive merger agreement with OPTN, under which, Paratek will acquire OPTN, including its approved product XHANCE (fluticasone propionate). After the transaction, OPTN shareholders will expect to receive $14 for each share, including the payment of contingent value rights (CVRs) tied to future commercial milestones. According to Paratek, the acquisition plan would boost its commercial portfolio beyond the flagship antibiotic NUZYRA. 'We have long recognized the potential of XHANCE to transform how CRS is treated. We have been exploring opportunities to make more patients and doctors aware of XHANCE and the benefits it can offer to patients suffering from this common condition. Paratek, with its robust commercial and medical capabilities, has the potential to rapidly extend awareness of XHANCE to primary care providers who treat the majority of patients with CRS,' said OPTN CEO Ramy Mahmoud. Overall, OPTN ranks 4th on our list of micro-, small-cap firms that dominate Thursday's gains. While we acknowledge the potential of OPTN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as OPTN but trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires Disclosure: None. This article is originally published at Insider Monkey.
